MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.63

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Lake Street CapitalInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
DateHeadline
06/23/16 10:39 AMCurrent report No 14/2016 - [at noodls] - The European Bank for Reconstruction and Development approved granting a new long-term loan for USD 20 million to ASTARTA to further finance its investment program. The proposed loan to ASTARTA Holding ...
06/21/16 06:00 AMAsterias Biotherapeutics Announces Oral Presentation and Participation in Panel Discussion at the ISSCR 14th Annual Meeting - [PR Newswire] - FREMONT, Calif., June 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative ...
06/20/16 01:02 PMETF’s with exposure to Asterias Biotherapeutics, Inc. : June 20, 2016 -
06/15/16 02:41 PMForm S-8 Asterias Biotherapeutics
06/15/16 02:41 PMInvestor Investigation over Potential Wrongdoing at Asterias Biotherapeutics Inc (NYSEMKT:AST)
06/14/16 04:07 PMASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 04:27 PMETF’s with exposure to Asterias Biotherapeutics, Inc. : June 7, 2016 -
06/07/16 10:50 AMASTERIAS BIOTHERAPEUTICS (AST) Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty
06/06/16 11:11 AMAsterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 07:38 AMIFC approved $25 million financing to ASTARTA - [at noodls] - The Board of Directors of International Financial Corporation (IFC) approved $25 million financing to ASTARTA in the form of working capital line. The Project will help the Company secure working capital ...
06/06/16 07:03 AMASTERIAS BIOTHERAPEUTICS (AST) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty - [Business Wire] - Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Asterias Biotherapeutics, Inc.
06/05/16 10:29 AMInvestor trolling, media hype and fetal stem cells
06/03/16 02:40 PMStemCells to wind down operations after ending mid-stage study
06/03/16 01:55 AMCurrent report No 13/2016 - [at noodls] - Current report No 13/2016 The text version of this document is not available at the moment. The original content was posted at original link . Astarta Holding NV published this content on 03 June 2016 ...
06/01/16 11:02 AMChardan Capital Starts Asterias Biotherapeutics at Buy, $5.50 PT (NYSEMKT:AST) - Analysts estimated a revenue of $870.00K. Thrivent Financial For Lutherans bought a new position in shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) during the fourth quarter, according to its most recent Form 13F filing with the SEC. Rodman & Renshaw ...
06/01/16 11:02 AMAre Analysts Bullish Asterias Biotherapeutics Inc (NYSEMKT:AST) After Last Week? - Rodman & Renshaw reissued a "buy" rating and set a $10.00 target price on shares of Asterias Biotherapeutics in a research note on Tuesday, May 17th. They now have a United States dollars 12 price target on the stock. The stock's market capitalization is $ ...
06/01/16 11:02 AMRecently Changed Price Targets On Asterias Biotherapeutics, Inc. (AST) - Chardan Capital's price target suggests a potential upside of 75.72% from the stock's current price. Out of 5 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 0 rate it a "Buy", 0 "Sell", while 0 "Hold". An institutional investor recently bought a ...
06/01/16 09:55 AMAsterias Biotherapeutics (AST): Moving Average Crossover Alert -
05/26/16 10:07 AMCurrent report No 12/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. with its corporate seat in Amsterdam, the Netherlands (the 'Company') informs that the following resolutions were adopted at the Annual General Meeting of ...
05/26/16 04:07 AMCurrent report No 11/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. with its corporate seat in Amsterdam, the Netherlands (the 'Company') informs that the following shareholders held at least 5% of voting rights at the Annual ...
05/23/16 12:49 PMChardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness - Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, saying the company "has the potential to become a significant competitor in the emerging fields of cell therapy and regenerative medicine." "Asterias is developing novel stem-cell based therapies in neurology and oncology, with three clinical-stage product candidates targeting cervical spinal cord injury, acute myelogenous leukemia and non-small cell lung cancer," Chardan explained. "We believe that Asterias' key advantage in developing its cell therapies is its access to the extensive knowledge about the unique properties of human pluripotent cells through its relationships with Geron and BioTime," analyst Keay Nakae wrote in a note. Catalysts According to the analyst, the following events should act as catalyst for the stock over the next year: 1. "Interim efficacy data at six months from the second patient cohort in ...Full story available on Benzinga.com
02/26/16 02:00 PMBioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy ... - Business Wire (press release) - BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy ...Business Wire (press release)ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics (“Asterias”), has ...Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1IT Business NetAsterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapyNews-Medical.netBioTime (BTX) Unit Completes End-of-Phase II FDA Meeting for AST-VAC1 in AMLStreetInsider.comall 7 news articles »
01/12/16 02:00 AMCurrent report No 2/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between January 4, 2016 and January 8, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, the ...
01/06/16 06:00 AMAsterias Biotherapeutics to Present at Biotech Showcase™ 2016 - [PR Newswire] - FREMONT, Calif., Jan. 6, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that Pedro ...
01/05/16 01:46 AMCurrent report No 1/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between December 28, 2015 and December 30, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, ...
12/29/15 09:08 AMASTARTA finished sugar production campaign - [at noodls] - Sugar plants of ASTARTA have successfully completed processing season with total sugar output of 355 thousand tonnes, including over 70% of premium quality sugar. Smooth weather conditions of this autumn ...
12/28/15 03:17 PMASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
12/25/15 04:21 AMCurrent report No 38/2015 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between December 21, 2015 and December 23, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, ...
12/24/15 09:38 AMAsterias Biotherapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/22/15 08:00 AMThe Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist - [Marketwired] - In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the ...
12/21/15 10:32 AMCurrent report No 37/2015 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between December 14, 2015 and December 18, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, ...
12/14/15 10:35 AMCurrent report No 36/2015 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between December 7, 2015 and December 11, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, ...
12/08/15 12:17 PMASTERIAS BIOTHERAPEUTICS, INC. Financials -
12/07/15 10:33 AMCurrent report No 35/2015 - [at noodls] - Notification concerning purchase of shares within the Buyback program The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between November 30, 2015 and December 04, 2015, during ...
11/30/15 10:35 AMCurrent report No34/2015 - [at noodls] - Notification concerning purchase of shares within the Buyback program The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between November 20, 2015 and November 27, 2015, during ...
11/19/15 06:23 PMDividend Reinvestment Plan Shareholder Communications - [at noodls] - f8f58c15-9683-44d6-bd5a-bc7a01c8be73.pdf 20 November 2015 TO: ASX Limited Singapore Exchange Securities Trading Limited Attached are the following documents relating to AusNet Services' Dividend Reinvestment ...
11/16/15 10:26 AMCurrent report No33/2015 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. (the Company) herby informs that between November 9, 2015 and November 13, 2015, during trading sessions on the main market of the Warsaw Stock Exchange, ...
11/10/15 03:27 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Asterias Biotherapeutics, Inc. - AST - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 10, 2015 / Levi & Korsinsky announces it has commenced an investigation of Asterias Biotherapeutics, Inc. (NYSE MKT: AST) concerning possible breaches of fiduciary ...
11/09/15 04:01 PMAsterias Biotherapeutics posts 3Q loss -
11/09/15 03:11 PMASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Finan -
About Asterias Biotherapeutics

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company's product development is focused primarily on AST-OPC1 and AST-VAC2. The Company's lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells, which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: AST
  • CUSIP:
Key Metrics:
  • Previous Close: $2.99
  • 50 Day Moving Average: $3.26
  • 200 Day Moving Average: $3.84
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $127.87M
  • Current Quarter EPS Consensus Estimate: $-0.88 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha